Publications by authors named "Montse Cortes"
Article Synopsis
- * Out of these patients, 8 experienced treatment intolerance with asciminib while 11 developed resistance; treatment strategies included dose adjustments of cTKIs or considering ponatinib despite previous non-candidacy.
- * The overall survival rate was 73% with the best outcomes for those intolerant to drugs (100%), while patients who progressed to advanced stages had a notably low survival rate (25%).
(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intolerant patients, as it is a first-in-class inhibitor with a more selective mechanism of action different from the ATP-competitive inhibition that occurs with TKIs. Therefore, our goal was to analyze toxicities shown with asciminib as well as to study cross-toxicity with previous TKIs.
View Article and Find Full Text PDFObjective: The predictive value of interim PET/computed tomography (I-PET/CT) in diffuse large B-cell lymphoma (DLBCL) is controversial. Our aim was to evaluate the predictive value of I-PET/CT for an event-free survival.
Patients And Methods: We analyzed patients with DLBCL included in a prospective clinical trial who were treated with six cycles of dose-dense R-CHOP followed by pegfilgrastim and who had undergone an I-PET/CT (after two cycles) and a final PET [F-PET/CT (60 days after the sixth cycle)].